CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 161 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2023. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $45,021,014 | -21.8% | 1,635,938 | -3.5% | 2.14% | -3.0% |
| Q2 2023 | $57,545,416 | -14.9% | 1,696,004 | -9.8% | 2.21% | -24.7% |
| Q1 2023 | $67,633,009 | -23.3% | 1,879,739 | -4.9% | 2.94% | -18.6% |
| Q4 2022 | $88,134,991 | +57.9% | 1,977,451 | -0.4% | 3.60% | +66.5% |
| Q3 2022 | $55,803,000 | -0.0% | 1,985,151 | -4.1% | 2.16% | +1.6% |
| Q2 2022 | $55,815,000 | -19.9% | 2,070,288 | +1.2% | 2.13% | -2.1% |
| Q1 2022 | $69,696,000 | -16.7% | 2,046,269 | -5.5% | 2.18% | +14.4% |
| Q4 2021 | $83,678,000 | -49.1% | 2,165,586 | -28.8% | 1.90% | -33.6% |
| Q3 2021 | $164,308,000 | +63.1% | 3,043,298 | +1.0% | 2.87% | +92.3% |
| Q2 2021 | $100,724,000 | +44.3% | 3,012,081 | -11.1% | 1.49% | +51.6% |
| Q1 2021 | $69,788,000 | +46.9% | 3,387,788 | +24.9% | 0.98% | +71.0% |
| Q4 2020 | $47,508,000 | +61.0% | 2,711,616 | +36.3% | 0.58% | +6.1% |
| Q3 2020 | $29,500,000 | +13.5% | 1,989,200 | -0.5% | 0.54% | +12.9% |
| Q2 2020 | $26,000,000 | – | 2,000,000 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |